<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641470</url>
  </required_header>
  <id_info>
    <org_study_id>DA9301_01</org_study_id>
    <nct_id>NCT02641470</nct_id>
  </id_info>
  <brief_title>The Effect of DA9301 on Tablet Computer-Induced Asthenopia</brief_title>
  <official_title>Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namyi Gu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DongGuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthenopia or eye strain describes nonspecific symptoms of an eye when it is tired from
      intensive work. Vaccinium uliginosum is a flowering plant in the genus Vaccinium. This plant
      is native to cool temperature regions of the Northern Hemisphere. Considering its
      antioxidative ingredients, the extract of Vaccinium uliginosum is expected to play a
      significant role in treating various ocular pathologies. The investigators performed a
      randomized, case-controlled study in healthy subjects and investigated the protective effect
      of Vaccinium uliginosum extract (DA-9301) on tablet computer-induced asthenopia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the modified questionnaire scores proposed by Ames et al.</measure>
    <time_frame>before and immediately after tablet computer use on Day 0 and Day 29 (deviation window: Day 21-31)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthenopia</condition>
  <arm_group>
    <arm_group_label>DA9301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally administration of placebo pills (1000 mg/day) for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DA9301 (Vaccinium uliginosum extract)</intervention_name>
    <arm_group_label>DA9301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Healthy subject aged 20 to 65 years with more than 2 hours of daily use of a smart phone
        or computer including a tablet and television

        Exclusion Criteria:

          1. Ocular disease in either eye

               -  Ocular surface disease

               -  Best corrected visual acuity &lt; 20/30

               -  Intraocular pressure &gt; 21 mmHg

               -  Optical coherence tomography proven retinal nerve fiber defect

               -  Significant cataract (lens opacities classification system III)

               -  Significant entropion or ectropion

               -  Significant tear drainage problem proved with fluorescein dye dilution test

          2. Soft or Hard contact lens use 3 or more days a week

          3. History of oral intake of health supplement designed to improve asthenopia within 4
             weeks before participating this study

          4. Pregnant woman

          5. Systemic disease

               -  Uncontrolled hypertension (systolic /diastolic blood pressure &gt; 140/90mmHg)

               -  Uncontrolled diabetes mellitus (fasting blood glucose level &gt; 180mg/dL)

               -  Rheumatoid arthritis

               -  Malignant disease

               -  Active hepatitis (type B and C)

               -  Acute or chronic infectious disease

               -  Renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choul Yong Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>oph0112@gmail.com</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>DongGuk University</investigator_affiliation>
    <investigator_full_name>Namyi Gu</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthenopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

